# OnCo record peter-schmid (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/peter-schmid/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "peter-schmid" ;
  schema:name "Peter Schmid"@en ;
  schema:description "Led KEYNOTE-522 and IMpassion130, the trials that brought immunotherapy into triple-negative breast cancer."@en ;
  schema:url <https://onco.cc/people/peter-schmid/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.bartscancer.london/>, <https://pubmed.ncbi.nlm.nih.gov/?term=Schmid%20P%5BAuthor%5D%20pembrolizumab%20triple-negative> ;
  onco:tag "tnbc", "immunotherapy", "trialist" ;
  schema:jobTitle "Professor of Cancer Medicine and Lead, Centre for Experimental Cancer Medicine, Barts Cancer Institute" ;
  schema:sameAs <https://orcid.org/0000-0001-9817-5228> ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:institutions <https://onco.cc/institutions/barts-cancer-institute/> ;
  onco:trials <https://onco.cc/trials/keynote-522/>, <https://onco.cc/trials/impassion130/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-522-nejm-2022/> ;
  schema:affiliation <https://onco.cc/institutions/barts-cancer-institute/> .